Motus GI Announces the Passing of Independent Director Dr. Sam Nussbaum
Motus GI Holdings, Inc. (NASDAQ: MOTS) announces the passing of independent director Samuel R. Nussbaum, MD, on September 23, 2021. Serving on the board since 2016, Dr. Nussbaum was a member of the compensation and nominating committees. His contributions to medical innovation and healthcare were acknowledged by CEO Tim Moran and Chairman David Hochman, who praised his leadership and mentorship. Dr. Nussbaum had extensive experience in healthcare and business, including roles at Anthem and consulting for life sciences and healthcare entities.
- None.
- Loss of experienced director may impact board effectiveness and strategic direction.
FORT LAUDERDALE, Fla., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) ("Motus GI" or the "Company") announced with profound sadness that Samuel R. Nussbaum, MD, an independent director on the Company’s board of directors, passed away on September 23, 2021. Dr. Nussbaum had proudly served on the Company’s board of directors since 2016, where he was a member of the compensation, and nominating and corporate governance committees.
“Sam served our Board with great commitment. He was an outstanding director, leader, and mentor, as well as a friend to all of us at Motus GI. We will miss him dearly and extend our deepest condolences to the entire Nussbaum family,” commented Tim Moran, Director and Chief Executive Officer at Motus GI.
David Hochman, Chairman of the Board, stated, “We are deeply saddened by the loss of a truly special human being. Sam was a person of the highest qualities, passionately committed to medical innovation and the improvement of healthcare delivery and outcomes. All of his work and interactions were guided by his love of people and passion for living. We were very fortunate to have the benefit of his service on our board of directors for the last five years. We will miss him greatly and his family is in our thoughts and prayers.”
Dr. Nussbaum was a highly accomplished senior executive with extensive medical and business experience across the healthcare and life sciences industries. For more than 16 years, he served as the Executive Vice President, Clinical Health Policy, and Chief Medical Officer of Anthem, Inc., where he was responsible for annual health care expenditures through business units focused on care management, health improvement, and provider network contracting. Most recently, Dr. Nussbaum spent the last five years as an influential strategic consultant for EBG Advisors, the consulting arm for Epstein Becker and Green, where he advised life science companies, health care systems, and provider organizations. Dr. Nussbaum also served as a Senior Advisor to Sandbox Industries, a venture fund, and the Ontario Teachers’ Pension Fund. Dr. Nussbaum earned his BA from New York University and his MD from Mount Sinai School of Medicine. He trained in internal medicine at Stanford University and Massachusetts General Hospital and in endocrinology at Harvard Medical School and Massachusetts General Hospital.
About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.
Investor Contact:
Bob Yedid
LifeSci Advisors
(646) 597-6989
bob@lifesciadvisors.com
FAQ
When did Samuel Nussbaum pass away?
What role did Samuel Nussbaum have at Motus GI?
How long did Dr. Nussbaum serve on the Motus GI board?
What was Dr. Nussbaum's background?
What is Motus GI Holdings, Inc. known for?
